Axis-Shield

Under the terms of the agreement, the financial details of which were not disclosed, Bio-Rad will have the right to develop the heparin binding protein marker for use on its proprietary laboratory instruments worldwide.

Under the terms of the agreement, Bio-Rad will have the right to develop the HBP marker for use on its proprietary laboratory instruments globally. Additional terms of the deal were not disclosed.

With FDA clearance, the test, which had been available outside the US, will now become available in the US.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.